Apellis shares are trading lower after the company announced the CHMP has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy.
Apellis Pharmaceuticals +2.47% Pre
Apellis Pharmaceuticals APLS | 27.34 27.34 | +2.47% 0.00% Pre |
Apellis shares are trading lower after the company announced the CHMP has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy.